Search Results - "Uziely, B."

Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer by Moss, J., Zick, A., Grinshpun, A., Carmon, E., Maoz, M., Ochana, B.L., Abraham, O., Arieli, O., Germansky, L., Meir, K., Glaser, B., Shemer, R., Uziely, B., Dor, Y.

“…Tumor-derived circulating cell-free DNA (cfDNA) is present in the plasma of individuals with cancer. Assays aimed at detecting common cancer mutations in cfDNA…”
Get full text

Key role for liquid biopsy in the elimination of breast cancer surgery following neoadjuvant therapy by Grinshpun, A., Moss, J., Uziely, B.

Get full text

PH motifs in PAR1&2 endow breast cancer growth by Kancharla, A., Maoz, M., Jaber, M., Agranovich, D., Peretz, T., Grisaru-Granovsky, S., Uziely, B., Bar-Shavit, R.

“…Although emerging roles of protease-activated receptor 1&2 (PAR 1&2 ) in cancer are recognized, their underlying signalling events are poorly understood. Here…”
Get full text

PH-domains as central modulators driving tumor growth by Bar-Shavit, R., Grisaru-Granovsky, S., Uziely, B.

Get full text

Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial by Sonnenblick, A., Bailey, A., Uziely, B., Untch, M., Smith, I., Gianni, L., Baselga, J., Jackisch, C., Cameron, D., Bell, R., Zardavas, D., Al-Sakaff, N., Gelber, R., Dowsett, M., Leyland-jones, B., Piccart, M., de Azambuja, E.

Get full text

Protease-activated receptors (PARs) in cancer: Novel biased signaling and targets for therapy by Bar-Shavit, R, Maoz, M, Kancharla, A, Jaber, M, Agranovich, D, Grisaru-Granovsky, S, Uziely, B

“…Despite the fact that G protein-coupled receptors (GPCRs) mediate numerous physiological processes and represent targets for therapeutics for a vast array of…”
Get full text

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation by Muggia, F M, Hainsworth, J D, Jeffers, S, Miller, P, Groshen, S, Tan, M, Roman, L, Uziely, B, Muderspach, L, Garcia, A, Burnett, A, Greco, F A, Morrow, C P, Paradiso, L J, Liang, L J

“…A phase II study of liposomal doxorubicin was conducted in patients with ovarian cancer who failed to respond to platinum- and paclitaxel-based regimens…”
Get more information

1963 First prospective outcome data in 930 patients with more than 5 year median follow up in whom treatment decisions in clinical practice have been made incorporating the 21-Gene Recurrence Score by Stemmer, S, Steiner, M, Rizel, S, Ben-Baruch, N, Soussan-Gutman, L, Rosengarten, O, Geffen, D, Nisenbaum, B, Ryvo, L, Uziely, B, Fried, G, Svedman, C, Rothney, M, Klang, S, Kaufman, B, Isaacs, K, Evron, E, Zidan, J, Shak, S, Liebermann, N

Get full text

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies by Uziely, B, Jeffers, S, Isacson, R, Kutsch, K, Wei-Tsao, D, Yehoshua, Z, Libson, E, Muggia, F M, Gabizon, A

“…The purpose of our studies was to define the maximal-tolerated dose of liposomal doxorubicin (DOX-SL; Liposome Technology Inc, Menlo Park, CA), a doxorubicin…”
Get more information

Effects of age on coping and psychological distress in women diagnosed with breast cancer: review of literature and analysis of two different geographical settings by Baider, L., Andritsch, E., Uziely, B, Goldzweig, G, Ever-Hadani, P, Hofman, G, Krenn, G, Samonigg, H.

“…Age-related differences in emotional distress were examined by studying two random samples ( N=424) of women diagnosed with early stages of breast cancer in…”
Get full text

Recurrence score results in elderly patients with estrogen receptor positive early breast cancer by Steiner, M, Ciuraru, N.B, Nisenbaum, B, Ryvo, L, Uziely, B, Geffen, D, Drumea, K, Leviov, M, Rizel, S, Stemmer, S

Get full text

Prognostic Significance of Cytokeratin Markers in Breast Cancer –a Meta Analysis by Barak, V, Uziely, B, Hubert, A, Nisman, B, Goike, H, Einarsson, R, Peretz, T

Get full text

Changes in psychological distress of women in long-term remission from breast cancer in two different geographical settings: a randomized study by Andritsch, E, Goldzweig, G, Samonigg, H, Uziely, B, Ever-Hadani, P, Hoffman, G, Krenn, G, Baider, L

“…Psychological distress and coping styles in women diagnosed with stages I and II breast cancer have attracted substantial clinical and research attention over…”
Get full text

Re: Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Metastatic Hormone-Refractory Prostate Cancer by Grenader, Tal, Shavit, Linda, Uziely, Beatrice, Peretz, Tamar

“…PTH release. PTH increases serum calcium concentration by activating bone…”
Get full text

Do different cultural settings affect the psychological distress of women with breast cancer? A randomized study by BAIDER, L., ANDRITSCH, E., UZIELY, B., EVER-HADANI, P., GOLDZWEIG, G., HOFMANN, G., SAMONIGG, H.

“…Breast cancer is the most common malignant disease among women in developed countries. In Austria and Israel, it accounts for 15% and 18%, respectively, of all…”
Get full text

Progressive muscle relaxation and guided imagery in cancer patients by Baider, L, Uziely, B, De-Nour, A K

“…The aim of this study was to gather information on the immediate and long-term effects of six sessions of group Progressive Muscle Relaxation with Guided…”
Get more information

Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer by Shushan, Asher, Peretz, Tamar, Uziely, Beatrice, Lewin, Aby, Mor-Yosef, Shlomo

“…OBJECTIVE: Our purpose was to investigate the frequency of ovarian cysts in tamoxifen-treated breast cancer patients. STUDY DESIGN: The study population…”
Get full text

The effect of tamoxifen on the endometrium by UZIELY, B, LEWIN, A, BRUFMAN, G, DOREMBUS, D, SHLOMO MOR-YOSEF

“…Tamoxifen is one of the most important treatments for breast cancer, especially in postmenopausal patients. It acts primarily as an anti-estrogenic agent, due…”
Get full text

218PAutoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial by Sonnenblick, A, Bailey, A, Uziely, B, Untch, M, Smith, I, Gianni, L, Baselga, J, Jackisch, C, Cameron, D, Bell, R, Zardavas, D, Al-Sakaff, N, Gelber, R, Dowsett, M, Leyland-jones, B, Piccart, M, de Azambuja, E

Get full text

Low doses of dexamethasone protect against paclitaxel (Taxol)-related hypersensitivity reactions following cycle 1 by Uziely, B, Jeffers, S, Muggia, F

Get more information